Jacobson L S, Schoeman T, Lobetti R G
Department of Companion Animal Medicine, Faculty of Veterinary Science, University of Pretoria, Onderstepoort, South Africa.
J S Afr Vet Assoc. 2000 Dec;71(4):222-8. doi: 10.4102/jsava.v71i4.719.
South Africa appears to be the only country where feline babesiosis is a significant clinical entity in domestic cats. Little is known about its epidemiology or the clinical challenges facing practitioners. A questionnaire posted to 1760 South African veterinarians was returned by 16%, representing approximately 40% of practices. Just over half reported seeing feline babesiosis, with most cases occurring in the coastal areas of the Western Cape, Eastern Cape and KwaZulu-Natal Provinces. Overall incidence is highest in summer, but seasonality is less pronounced in non-seasonal and winter rainfall areas. No age, breed or sex predisposition was identified. Weight loss, weakness, anaemia, fever and icterus are common clinical findings. Complications include hepatopathy, renal failure, pulmonary oedema, cerebral signs, immune-mediated haemolytic anaemia and concurrent infections. The antibabesial drug of choice is primaquine phosphate. Response to therapy is generally good, but recurrence and chronic infections were identified as problems. The average mortality rate was 15%. Approximately 3000 cases are seen annually by the respondents, at an estimated cost of R750 000 to the owners. Feline babesiosis is a significant problem in South Africa, and further investigations of taxonomic status, concurrent infections, chemotherapy, complications and management of refractory cases are warranted.
